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Johann Steiner1, Martin Walter1,2 and Bernhard Bogerts1
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There is increasing evidence for disturbances within the glutamate system in patients
with affective disorders, which involve disruptions of the glutamate–glutamine-cycle.
The mainly astroglia-located enzyme glutamine synthetase (GS) catalyzes the ATP-
dependent condensation of ammonia and glutamate to form glutamine, thus playing
a central role in glutamate and glutamine homoeostasis. However, GS is also expressed
in numerous oligodendrocytes (OLs), another class of glial cells implicated in mood
disorder pathology. To learn more about the role of glia-associated GS in mental
illnesses, we decided to find out if numerical densities of glial cells immunostained for the
enzyme protein differ between subjects with major depressive disorder, bipolar disorder
(BD), and psychically healthy control cases. Counting of GS expressing astrocytes (ACs)
and OLs in eight cortical and two subcortical brain regions of subjects with mood
disorder (N = 14), BD (N = 15), and controls (N = 16) revealed that in major depression
the densities of ACs were significantly reduced in some cortical but not subcortical gray
matter areas, whereas no changes were found for OLs. In BD no alterations of GS-
immunoreactive glia were found. From our findings we conclude that (1) GS expressing
ACs are prominently involved in glutamate-related disturbances in major depression, but
not in BD and (2) GS expressing OLs, though being present in significant numbers in
prefrontal cortical areas, play a minor (if any) role in mood disorder pathology. The latter
assumption is supported by findings of others showing that – at least in the mouse
brain cortex – GS immunoreactive oligodendroglial cells are unable to contribute to
the glutamate–glutamine-cycle due to the complete lack of amino acid transporters
(Takasaki et al., 2010).
Keywords: major depression, bipolar disorder, cortex, glutamine synthetase, astroglia, oligodendroglia,
immunocytochemistry
Abbreviations: AC(s), astrocyte(s); Aic, anterior insular cortex; ANOVA, A single-factor analysis of variance; ATP,
adenosine triphosphate; BD, bipolar disorder; CNS, Central Nervous System; DLPFC, dorso-lateral prefrontal cortex; GABA,
γ-Aminobutyric acid; DSM-IV; Diagnostic and Statistical Manual of Mental Disorders IVth edition; GFAP; glial ﬁbrillary
acidic protein; Glx, glutamate-glutamine-GABA complex; GS, glutamine synthetase; MANOVA, Multivariate analysis of
covariance; MDD, major depression disorder; MSR, Magnetic Resonance Spectroscopy; OL(s), oligodendrocyte(s); n.a., not
available; NAc, Nuc. Accumbens; pACC, pregenual anterior cingulate; PBS, Phosphate buﬀered saline; sACC, subgenual
anterior cingulate cortex.
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Introduction
Initially, search for the possible cellular substrate of mood
disorder pathology had focused on neurons (Rajkowska, 2000,
2002; Cotter et al., 2001a,b, 2002; Manji et al., 2001). However,
during the last years a wave of information appeared to
suggest that glial cells prominently, and in many ways,
contribute to brain structural and functional changes in mood
disorders. In numerous histological postmortem investigations
both signiﬁcantly reduced (Öngür et al., 1998; Rajkowska, 2000;
Cotter et al., 2001a,b; Hamidi et al., 2004; Uranova et al., 2004;
Rajkowska and Miguel-Hidalgo, 2007; Altshuler et al., 2010; Gos
et al., 2013) and increased (Davis et al., 2002; Mosebach et al.,
2013; Malchow et al., 2014) glial cell numbers and numerical
densities have been observed in prefrontal cortex areas and limbic
regions. In addition, characteristic changes in gene expression
patterns and metabolic pathways of glial cells have been found
in aﬀective disorders (reviewed in Barley et al., 2009; Steiner
et al., 2012; Mosebach et al., 2013; Duncan et al., 2014; Schroeter
et al., 2014; Bernstein et al., 2015). Of note, each of the three glial
cell classes (i.e., ACs, OLs, and microglia) appears to confer its
unique contribution to the pathophysiology of aﬀective disorders.
Moreover, their impact may be diﬀerent in MDD (Verkhratsky
et al., 2014) and in BD, (Savitz et al., 2014; Dong and Zhen,
2015). In this context, much attention has been paid to the
possible role of ACs in MDD and BD pathology. Being the
most prevalent cell type in the human brain, ACs serve a wide
range of diﬀerent functions in the CNS. They play important
roles in synaptic transmission, control of neuronal metabolism,
sensing of brain microenvironment, maintenance of blood-
brain barrier integrity, brain defense and inﬂammatory processes
(Sofroniew and Vinters, 2010; Teschemacher et al., 2015). Since
synaptic, metabolic and inﬂammatory dysregulation are reported
in MDD and BD (Harrison, 2002; Si et al., 2004; Kato et al.,
2013; Duman, 2014; Maletic and Raison, 2014; and others),
AC abnormalities may be implicated in these disorders. ACs
exert inﬂuence on cerebral information processing mainly in two
ways: (1) they release, by exocytosis, gliotransmitters (glutamate,
D-serine, GABA and ATP, Sahlender et al., 2014), which facilitate
the communication between neurons and neuron-glia crosstalk,
and (2) they remove glutamate from extracellular space and
provide glutamatergic and GABAergic neurons with glutamine,
which they synthesize from glutamate, ammonia and ATP
(Anlauf and Derouiche, 2013). Theoretically, impaired release
of gliotransmitters (Van Horn et al., 2013) and/or compromised
glutamate uptake and recycling by ACs might signiﬁcantly
contribute to anomalies of glutamatergic (and, most probably,
GABAergic) neurotransmission reported in MDD and BD (for
reviews, see Walter et al., 2009; Brennan et al., 2010; Gigante
et al., 2012; Salvadore et al., 2012; Bernstein et al., 2013; Dou
et al., 2013; Duman, 2014; Arnone et al., 2015; Pehrson and
Sanchez, 2015). However, while knowledge about the possible
impact of gliotransmitters on mood disorder pathology is
still fragmentary (Etiévant et al., 2013), there is some good
evidence in favor of impaired AC-related glutamate-glutamine
cycling as an important contributing factor in aﬀective disorders
(reviewed in detail by Bernstein et al., 2013 and Rajkowska
and Stockmeier, 2013). Due to its central position in the
glutamate–glutamine–GABA cycle, the glutamine-synthesizing
enzyme GS (aka glutamate-ammonia ligase, EC 6.3.1.2) came
early into focus of research, and a number of papers have
meanwhile been published about alterations in GS in MDD
and BD. In subjects with MDD a majority of studies show
a decrease of cerebral GS. The expression of GS mRNA was
reported to be down-regulated in the prefrontal cortex, the
premotor cortex, and the amygdala of depressed suicide victims
but not in suicide completers without depression (Choudary
et al., 2005; Sequeira et al., 2009), whereas GS protein was
found to be reduced in the anterior cingulate cortex and the
orbitofrontal cortex (Choudary et al., 2005; Beasley et al., 2006;
Miguel-Hidalgo et al., 2010; Rajkowska and Stockmeier, 2013).
However, no alterations in cortical GS of MDD subjects were
found by others (Toro et al., 2006). The implication of GS for
BD is less well explored, and the sparse data are inconsistent.
GS expression was reported unchanged (Toro et al., 2006) or
decreased (Choudary et al., 2005) in the prefrontal cortex of
bipolar subjects. Remarkably, all but one (Toro et al., 2006)
studies on GS expression in mood disorders used biochemical
techniques. Thus, little attention has yet been paid to the type
of GS-expressing cells, although there is evidence that GS can
also be detected in extra-astroglial localizations [i.e., in numerous
OLs and even in some neurons (Takasaki et al., 2010; Iwata
et al., 2013; Bernstein et al., 2014 and others)]. Thus, theoretically,
disease-related alterations of GS expression might involve non-
astroglial cells, too. We, therefore, counted GS expressing glial
cells in ten diﬀerent cortical and subcortical brain areas of
subjects with MDD, BD, and psychically healthy controls and
show herein that (1) signiﬁcantly reduced densities of GS-
immunoreactive glial cells occur in cortical areas of MDD, but
not BD subjects and (2) these changes are restricted to GS
expressing ACs, whereas GS expressing OLs are normal in mood
disorders.
Materials and Methods
Subjects
All brains were obtained from the New Magdeburg brain
collection. Case recruitment, acquisition of personal data,
performance of autopsy, and handling of autoptic material were
conducted in strict accordance with the Declaration of Helsinki,
and have been approved by the responsible Ethical Committee
of Magdeburg. Written consent was obtained from the next-of-
kin. Information for clinical diagnoses was obtained from clinical
records and/or structural interviews of physicians involved in
treatment or relatives (Bielau et al., 2005).
Brains of 29 human subjects with mood disorders according
to DSM-IV were studied. Of these individuals 14 (8 female, 6
male; mean age: 46.9 ± 11.4 years) had suﬀered from a MDD
and 15 (5 female, 10 male; mean age: 53.5 ± 10.4 years) had
a BD. Sixteen control individuals (9 female, 7 male; mean age:
50.4 ± 11.0 years) without a history of neuropsychiatric disorder
were also investigated. None of the patients or controls had
a history of substance abuse or alcoholism. Neuropathological
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changes due to neurodegenerative or traumatic processes were
ruled out by an experienced neuropathologist as previously
described (Bielau et al., 2005). These cases were matched
with respect to age, gender, and autolysis time. The matching
processes were done prior to all analyses. For demographical,
clinical, and psychopharmacological details see Tables 1 and 2.
The mean daily doses of psychotropic medication taken by
patients during the last 90 lifetime days were established
according to the clinical ﬁles. Since our brain bank has
been established about 25 years ago, patients received tricyclic
antidepressants instead of selective serotonin or noradrenalin
reuptake inhibitors (for detailed considerations, see Mosebach
et al., 2013).
Tissue Processing
Brains were removed within 4–96 h after death and ﬁxed in toto
in 8% phosphate-buﬀered formaldehyde for at least 2 months
(pH = 7.0, T = 15–20◦C).
Frontal and occipital poles were separated by coronal cuts
0.9 cm anterior to the genu and posterior to the splenium of the
corpus callosum. After embedding of all parts of the brains in
paraﬃn, serial coronal sections of the prefrontal and the middle
blocks were cut (20 μm) and mounted. The shrinkage factor
caused by ﬁxation and embedding of the brains was calculated
by a method described previously (Bernstein et al., 1998a).
The mean volume shrinkage factor for patients with aﬀective
disorders and controls was 2.21. No signiﬁcant diﬀerences in the
shrinkage factors among the three groups MDD, BP, and controls
were found. Every 50th section was Nissl and myelin stained as
described previously (Bernstein et al., 1998b).
Glutamine Synthetase Immunohistochemistry
For immunohistochemical stainings, whole brain sections were
collected at intervals of about 0.2 cm between 1.8 and 1 cm rostral
to the genu of the corpus callosum. The pACC, (Brodmann
Area 32) and dorsolateral prefrontal (DLPFC, Brodmann Area 9)
cortices were easily identiﬁable using the “Atlas of the Human
Brain” by Mai et al. (2003). Sections containing the left and
right sACC, Aic, (Brodmann area 14), and the NAc were selected
at intervals of 0.2 cm. To immunolocalize GS, we employed a
well-characterized, monospeciﬁc polyclonal antiserum generated
in rabbits against human GS (Prestige Antibody HPA 007316;
Lot C 81287; from Sigma–Aldrich, Munich, Germany). Since
diﬀerent lots of the same antibody may considerably diﬀer
with regard to their staining properties (Couchman, 2009), we
tested three diﬀerent lots of the GS antiserum HPA 007316
(namely A42599, C81287, R04375). In our hands all three lots
were of the same superior quality, and we decided to continue
working with Lot C 81287. After dewaxing antigen demasking
was carried out by boiling the sections for 4 min in 10 mM citrate
buﬀer (pH 6.0). Thereafter, the sections were pre-incubated
with methanol/H2O2 to suppress endogenous peroxidases and
repeatedly washed with PBS. Subsequently, the primary GS
antibody was applied at a dilution of 1:500 for 72 h at 4◦C.
Sections were then incubated with a biotinylated anti rabbit
IgG (Amersham Bioscience, Buckinghamshire, GB), followed by
the streptavidin horse radish complex for the application of the
streptavidin–biotin technique (Amersham). The chromogen 3,3′-
diaminobenzidine was used to visualize the reaction product.
Subsequently, ammonium nickel sulfate hexahydrate was added
to enhance the immunoreaction (Bernstein et al., 2013). For
control purposes, the primary antiserum was replaced by either
buﬀer or normal serum. Further control experiments involved
the application of the GS antiserum after preabsorption with
GS protein (recombinant human GS, charge number CE02;
from Novoprotein, Shanghai, China) as described earlier in
detail (Bernstein et al., 2014). When these controls were
done the investigated regions did not show any speciﬁc
immunostaining.
Glial Fibrillary Acidic Protein (GFAP)
Immunohistochemistry
For reasons of comparison and better delineation of cortical gray
matter areas sections adjacent to GS immunostained ones were
immunolabeled for GFAP. Amonoclonal antibody (diluted 1:100
in PBS, from DAKO) was used. The secondary antibody was an
anti-mouse peroxidase (from Biozol, Eching, Germany; dilution
1:50). The working dilution was 1:2000. Visualization was as
described for GS. Controls involved replacement of the primary
antiserum by either buﬀer or normal serum.
Cell Countings
The actual section thickness after the histological procedures
was 18.9 ± 1.0 μm (mean ± SD). The optical disector cell-
counting method was employed. Cell countings were performed
in two coronal sections per brain area under blind conditions.
A counting grid was used to deﬁne a three-dimensional box
within the thickness of the section as described previously
(Bernstein et al., 1998b) allowing at least 4 μM guard zones at
the top and bottom of the section, and to apply a direct, three-
dimensional counting method. Fifteen consecutive boxes per left
and right cortical area were positioned, spanning the layers I
and II, layer III, and another 15 spanning the layers IV, V, and
VI, thus subdividing cortical gray matter regions into superﬁcial
and deep layers as proposed by Katsel et al. (2011). To count
immunostained cells in the NAc we used 15 boxes per section and
hemisphere. The packing densities of glial cells are noted as the
number of cells × 103/mm3. The product of the volume and glial
cell density provided the total cell number estimates. The inter-
rater reliability was about 0.87. In a few cases we observed some
local tissue damage in the brain region of interest. Cell counts
of these particular regions were rigorously excluded from further
calculations, which resulted in smaller cohorts than nominally
indicated (for example, number of right NAc in MDD subjects:
12 instead of 14 cases).
Statistical Analysis
A single-factor analysis of variance was performed using
diagnostic groups as a three-level independent variable (MDD
patients versus BD versus non-psychiatric controls) and
measured and calculated parameters were treated as dependent
variables. MANOVA was performed with diagnosis and side,
ie., left and right hemisphere, as independent variables (repeated
measures). Eﬀect sizes were determined for 3-group comparisons
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TABLE 1 | Demographical data of patients and controls.
Diagnosis case Gender Age (years) Postmortem autolysis time (h) Duration of illness/years Cause of death
MDD (n = 14)
1 Male 42 5 n.a. Suicide (hanging)
2 Female 39 48 7 Suicide (benzodiazepines overdose)
3 Female 46 48 11 Suicide (hanging)
4 Female 53 48 n.a. Suicide (hanging)
5 Female 63 17 2 Pulmonary embolism
6 Female 61 70 11 Heart failure
8 Male 35 24 2 Suicide (slitting of the wrists)
9 Male 36 48 1 Suicide (hanging)
10 Male 42 24 n.a. Acute pancreatitis
11 Male 30 24 n.a. Suicide (hanging)
12 Female 60 24 1 Suicide (hanging)
13 Female 59 48 4 Suicide (hanging)
14 Female 35 24 n.a. Suicide (strangulation)
15 Male 55 24 n.a. Suicide (strangulation)
8 Female/6 Male 46.9 ± 11.4 34.0 ± 17.6 4.9 ± 4.3
BD (n = 15)
16 Male 47 24 9 Suicide (stabbing)
17 Female 46 4 13 Suicide (tablet intoxication)
18 Male 42 12 16 Suicide (hanging)
19 Female 62 72 11 Pulmonary embolism
21 Male 39 24 2 Pulmonary embolism
22 Female 59 72 24 Suicide (tablet intoxication)
23 Male 39 56 14 Myocardial infarction
24 Male 69 48 26 Pulmonary embolism
25 Male 69 24 18 Heart failure, pulmonary embolism
26 Female 52 24 16 Heart failure, pulmonary embolism
27 Female 65 52 25 Heart failure
28 Male 44 96 6 Trombosis after myocardial infarction
29 Male 57 48 n.a. Suicide (strangulation)
30 Male 60 24 5 Suicide (strangulation)
31 Male 53 24 1 Suicide (strangulation)
5 female/10 Male 53.5 ± 10.4 40.3 ± 25.8 13.3 ± 8.2
Depression 13 female/16 Male 50.3 ± 11.2 37.2 ± 22.1 10.2 ± 8.1
Controls (n = 16)
31 Male 56 48 0 Retroperitoneal hemorrhage
34 Female 52 24 0 Heart failure, renal insufficiency
35 Female 48 48 0 Status asthmaticus
38 Female 33 72 0 Aortic embolism
39 Female 50 72 0 Ruptured aortic aneurysm
40 Male 40 96 0 Myocardial infarction
41 Male 64 36 0 Ruptured aortic aneurysm
42 Female 48 26 0 Pulmonary embolism
43 Male 56 24 0 Myocardial infarction
44 Female 65 24 0 Heart failure
45 Female 30 48 0 Pulmonary embolism
46 Male 63 48 0 Heart failure (after heart surgery)
47 Female 38 24 0 Heart failure
48 Male 54 24 0 Pulmonary embolism
49 Male 46 24 0 Heart failure, cancer
50 Female 63 24 0 Myocardial infarction
9 Female/7 Male 50.4 ± 11.0 41.4 ± 22.2 −
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TABLE 2 | Psychopharmacological treatment.
Case Mean antidepressiva dose
of the last days [mg]
Mean neuroleptics dose of
the last days [mg]
Mean benzodiazepine
dose of the last days [mg]
Mean carbamazepine
dose of the last days [mg]
Mean lithium dose of the
last days [mg]
MDD (n = 14)
1 n.a. n.a. n.a. n.a. n.a.
2 93 0 3 0 560
3 124 109 0 0 0
4 0 0 0 0 0
5 50 0 0 0 0
6 30 111 16 0 0
8 0 0 0 0 0
9 0 0 0 0 0
10 200 200 n.a. n.a. n.a.
11 100 100 n.a. n.a. n.a.
12 100 440 0 0 0
13 n.a. n.a. n.a. n.a. n.a.
14 n.a. n.a. n.a. n.a. n.a.
BD (n = 15)
16 20 0 0 0 0
17 133 327 3 0 558
18 95 47 18 0 565
19 0 110 18 0 0
21 0 280 0 0 0
22 112 0 10 600 0
23 0 221 1 0 740
24 0 0 7 0 0
25 0 0 2 0 280
26 0 n.a. n.a. n.a. n.a.
27 93 117 4 0 0
28 n.a. n.a. n.a. n.a. n.a.
29 n.a. n.a. n.a. n.a. n.a.
30 n.a. n.a. n.a. n.a. n.a.
31 150 200 0 200 0
(major depressive disorder, BD, controls). Confounding
variables including whole brain volume were primarily tested on
normality by use of the Kolmogorov–Smirnov test. A post hoc
Tukey HSD test was conducted to determine which variables
were signiﬁcantly diﬀerent from each other. Pearson correlation
tests were carried out to investigate eﬀects of postmortem delay,
time of ﬁxation, illness duration, number of illness episodes,
and psychotropic medication (i.e., antidepressants, neuroleptics,
benzodiazepines, and lithium) on data. In addition, emphasis
was given to suicide as possible confounding factor. P-values less
than 0.05 were deemed to be statistically signiﬁcant.
Results
Qualitative Observations
Glutamine Synthetase Immunostaining
Astrocytes
Glutamine synthetase -immunoreactive ACs were abundantly
present in the cerebral cortex and the NAc. Their morphology
was remarkably consistent. Astrocytic somata and processes
were prominently stained for GS. In addition, an intense
immunostaining was observed in the neuropil. Numerous blood
vessels were surrounded by GS-immunoreactive AC endfeet.
Oligodendrocytes
Gray matter GS-immunoreactive OLs were easily identiﬁable
based on their typical morphology. The immunoreaction
was conﬁned to the cell somata. Short processes were only
infrequently immunolabeled. Immunopositive OLs were fairly
uniformly distributed throughout prefrontal cerebral cortex.
However, in the AiC and the NAc GS-expressing OLs were
relatively rarely found. Therefore, we did not count them
separately in the latter two brain regions. Examples for the
immunolocalization of GS in ACs and OLs are given in
Figures 1A–I. Figure 1J shows a control reaction.
GFAP Immunostaining
In all cortical areas GFAP protein was expressed in a majority of
ACs. Their distribution showed a laminar pattern. The highest
package density of GFAP was found in layers I (where ACs abut
at the pial surface of the brain, Miguel-Hidalgo et al., 2010) and
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FIGURE 1 | Immunolocalization of GS in cortical and subcortical human
brain glial cells in MDD, BD, and controls. (A) GS-immunoreactive ACs and
OLs (asterisk) in the pACC (control case). Bar = 20 μm. (B) GS-immunoreactive
ACs and OLs (asterisks) in the pACC (MDD subject). Bar = 20 μm.
(C) GS-immunoreactive ACs and OLs (asterisk) in the pACC (BD subject).
Bar = 20 μm. (D) GS-immunoreactive ACs and OLs (asterisks) in the sACC
(control case). Bar = 20 μm.(E) GS-expressing ACs and OLs (asterisk) in the
sACC (MDD subject). Bar = 20 μm.(F) GS-expressing ACs and OLs (asterisk) in
the DLPFC (BD subject). Bar = 20 μm. (G) GS-immunopositive ACs in the AiC
(control case). Bar = 20 μm. (H) GS-expressing ACs in the NAc (control case).
Bar = 24 μm. (I) GS-immunoreactive OLs (asterisks) in the pACC (control case).
Bar = 20 μm. (J) Specificity control reaction. After preabsorption of the primary
antiserum with recombinant GS protein no specific immunostaining is visible.
Bar = 30 μm.
II. In the NAc an even distribution of GFAP immunolabeled cell
elements was observed. OLs did not express GFAP.
Quantitative Estimates
We could replicate our own ﬁndings (Bernstein et al., 2014)
as well as results previously published by others (Toro et al.,
2006) that there is a higher density of GS-expressing cells in
superﬁcial cortical layers I–III than in deeper cortical layers IV–
VI. It is therefore justiﬁed to count superﬁcial and deeper layers
separately.
In subjects with mood disorder signiﬁcantly reduced
numerical densities of GS immunoreactive ACs were found the
DLPFC (left side, layers I–III, p = 0.029; F = 4.487 and right
side, layers I–III; p = 0.046; F = 3.647), sACC (left side, layers
I–III, p = 0.021; F = 4.304), AiC (left side, layers I–III, p = 0.002;
F = 7.893; right side, layers I–III, p = 0.001; F = 9.789; ride side,
layers IV–VI, p = 0.015; F = 5.136). No signiﬁcant changes were
detectable in the pACC and the NAc. All but one (DLPCC right
side, layers I–III) signiﬁcant changes survived Tukey’s HSD post
hoc tests. Notably, no signiﬁcant alterations in the numerical
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densities of OLs were found. Results of the morphometric
analyses are shown in Figures 2–6.
MDD vs. controls
Compared with controls a signiﬁcant reduction in the numerical
densities of GS-immunopositive ACs was found in MDD in ﬁve
of the 10 cortical and subcortical brain regions studied: DLPFC
(left side, layers I–III, p = 0.024), sACC (left side, layers I–III,
p = 0.018); AiC (left side, layers I–III; p = 0.002; right side, layers
I–III; p = 0.001; F = 9.962; right side, layers IV–VI, p = 0.012).
BD vs. controls
In BD cases the numerical densities of GS-expressing ACs and
OLs did not signiﬁcantly diﬀer from those of controls.
FIGURE 2 | Numerical densities of GS-expressing glial cells (ACs and OLs) in the DLPFC of subjects with MDD, BD, and controls. Compared with
controls the density of GS-expressing ACs is significantly reduced in MDD cases (AC left I–III, p = 0.029; AC right I–III, p = 0.046).
FIGURE 3 | Numerical densities of GS-expressing glial cells (ACs and OLs) in the pACC of subjects with MDD, BD, and controls. No significant
alterations were found in this brain region.
FIGURE 4 | Numerical densities of GS-expressing glial cells (ACs and OLs) in the sACC of subjects with MDD, BD, and controls. Compared with
controls the density of GS-expressing ACs is significantly reduced in MDD cases (AC left I–III, p = 0.021).
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FIGURE 5 | Numerical densities of GS-expressing glial cells (ACs and
OLs) in the AiC of subjects with MDD, BD, and controls. Compared with
controls the density of GS-expressing ACs is significantly reduced in MDD
cases (AiC left I–III, p = 0.002; AiC right I–III, p = 0.001; AiC right IV–VI,
p = 0.015).
FIGURE 6 | Numerical densities of GS-expressing glial cells (ACs and
OLs) in the NAc of subjects with MDD, BD, and controls. No significant
alterations were found in this brain region.
MDD vs. BD
Compared with BD cases subjects with MDD showed
signiﬁcantly decreased densities of GS-immunopositive ACs in
the DLPFC (right side, layers I–III, P = 0.047), in the AiC (left
side, layers I–III, p = 0.024; right side, layers IV.IV; p = 0.001).
Impact of Completed Suicide on Cell Densities
Since there are reports showing that GS expression is altered
in brains of suicide victims with and without mood disorder
(Kim et al., 2007; Sequeira et al., 2009; Bernstein et al., 2013)
we next analyzed the inﬂuence of the confounding factor “death
by suicide” on the densities of GS immunoreactive ACs in the
brain regions under study. For this purpose we divided MDD
and BD cases into subgroups of suicide victims (MDD: N = 11;
BD: N = 7) and depressed subjects who died of natural causes
(MDD: N = 3; BD: N = 8). With regard to MDD cases in none
of the brain regions there appeared signiﬁcant diﬀerences in the
densities of GS-expressing cells between depressed subjects dying
by suicide and non-suicidal individuals with MDD. The same
holds true for subjects with BD: Suicidal and non-suicidal BD
cases did not signiﬁcantly diﬀer with regard to glial cell densities
in any of the regions studied, as exempliﬁed for the AiC in
Figure 7. It should be emphasized, however, that the subgroup
of non-suicidal subjects with MDD is too small (N = 3) to come
to far-reaching conclusions from these data.
The Influence of Other Confounding Factors
Analysis of the potential confounding factors on the test results
revealed no signiﬁcant inﬂuence of age, gender, duration of
disease, or psychotropic medication. Especially the lack of
correlation between the age and the density of GS-expressing
ACs is interesting, because Rajkowska and Stockmeier (2013)
have hypothesized the glial pathology appears to apply mostly to
younger and middle age subjects with MDD (<60 years of age).
Possible Influence of Hemispheric Asymmetry on GS
Cell Distribution in Human Brain
There is evidence in the for structural, functional, and
physiological asymmetries in the two hemispheres of
human brain (comprehensively reviewed in Jayasundar and
Raghunathan, 1997), which involve aspects of glutamate and
GABA metabolism in health and mood disorder (MDD:
Pﬂeiderer et al., 2003; Bajbouj et al., 2006; Gos et al., 2012; BD:
Gos et al., 2012; Xu et al., 2013). The latter might in part result
from left–right hemispheric diﬀerences in the distribution of
GS immunoreactivity (Bernstein et al., 2013), Unfortunately,
knowledge about the catalytic activity and distribution of human
brain GS comes mainly from studies of only one (namely the
left) brain hemisphere (Burbaeva et al., 2003; Rajkowska and
Miguel-Hidalgo, 2007; Miguel-Hidalgo et al., 2010). To exclude
a possible left–right asymmetry of GS, we counted left and right
hemispheres separately. No evidence was found for a signiﬁcant
left–right asymmetry, neither in controls, nor in subjects with
aﬀective disorder.
Discussion
Major depression disorder and BD are serious mental illnesses
with multifactorial pathophysiologic characteristics. The
past years have witnessed a remarkable extension of our
understanding of the neurobiology of aﬀective disorders, adding
the glutamatergic and the GABAergic hypotheses to “classical”
monoaminergic theories of mood dysregulation (Delgado,
2000; Skolnick et al., 2009; Catena-Dell’Osso et al., 2013; Dou
et al., 2013; Hertz et al., 2014; Pehrson and Sanchez, 2015;
Schitine et al., 2015). Besides other indicators of compromised
amino acidergic neurotransmission in depression, two large
meta-analyses of neuroimaging ﬁndings have demonstrated
decreased levels of the Glx in adult MDD patients, whereas in
the brains of BD patients increased, decreased, and unchanged
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FIGURE 7 | Numerical densities of GS-expressing glial cells in the AiC of suicide completers with MDD, non-suicide completers with MDD, suicide
completers with BD, non-suicide completers with BD, and controls. No significant alterations were found.
glutamate and reduced glutamine levels have been measured
(Yüksel and Öngür, 2010; Gigante et al., 2012; Luykx et al.,
2012). Moreover, the NMDA receptor antagonist ketamine has
been shown in clinical trials to act as a rapid antidepressant in
MDD (for recent considerations, see DeWilde et al., 2015). The
acceptance of a crucial role of glutamate in the pathology of
mental disorders entails the obligatory implication of glial cells
(Arnone et al., 2015). Being part of the glutamatergic tripartite
synapse, intact ACs are central to a proper functioning of
glutamatergic neurotransmission, and imbalances in the neuron-
AC communication at the synaptic level might signiﬁcantly
contribute to aﬀective disorders, such as mania and depression
(Mitterauer, 2015; Thompson et al., 2015). The enzyme GS,
which is highly expressed in, but in its expression not restricted
to, ACs, is required to synthesize the non-toxic glutamine
from the re-uptake of either glutamate or GABA. Besides,
in human brain an immunologically and enzymatically very
closely related “sister” enzyme of (GS-like protein) of unknown
cellular localization was found (Boksha et al., 2000), which shows
altered expressions in schizophrenia and Alzheimer’s disease
(Burbaeva et al., 2003; Burbaeva et al., 2014). The possible
implication of GS-like enzyme for mood disorders is unexplored,
however. Keeping this in mind when designing this study,
we morphometrically analyzed GS-immunoreactive glial cells
located in various cortical and subcortical gray matter areas
of subjects with MDD and BD, thereby counting, wherever
possible, ACs and OLs separately. Signiﬁcantly reduced densities
of GS immunopositive ACs were found in the prefrontal areas
DLPFC and sACC as well as in the AiC of subjects with MDD.
Remarkably, the densities of GS-immunopositive OLs were
normal in all regions studied, although a signiﬁcant loss of
perineuronal OLs was found in prefrontal cortex sublayers IIIa,
b, and c in mood disorder by others (Vostrikov et al., 2007).
When carefully analyzing cortical GS-expressing OLs in mice,
Takasaki et al. (2010) found that the enzyme protein is mainly
expressed in perineuronal OLs, with roughly half of them being
GS-immunopositive. However, these GS-immunoreactive OLs
lack plasmalemmal glutamate transporters GLAST and GLT-1,
thus apparently being unable to participate in the glutamate-
glutamine cycle. The reason why these cells even so express
GS remains enigmatic, but is seemingly not directly related to
glutamatergic synaptic neurotransmission (possibly playing a
role in cellular ammonia clearance and/or certain metabolic
support to the associating cortical neurons, Takasaki et al., 2010;
Bernstein et al., 2014). Thus, our data clearly show a cell-type
speciﬁc reduction in cortical GS expression in individuals with
MDD, which cannot be revealed when analyzing total GS protein
in brain samples with biochemical methods. Interestingly, we
found no indication for altered densities of GS-expressing ACs in
the NAc, although this brain region plays a central role in MDD
(Thompson et al., 2015) and has therefore been chosen as a target
structure for deep brain stimulation in cases of therapy-resistant
MMD (Bewernick et al., 2012). Although ACs play a critical
role in controlling the excitability of NAc neurons via activation
of glutamatergic receptors (Fellin et al., 2007; Thompson et al.,
2015), their possible implication for “human” depression” yet is
poorly explored. However, the number of ACs in the NAc was
found to be unchanged in a developmental “toxic stress” model
of depression (Shende et al., 2015).
Unlike in MDD, no alterations in the density of GS-expressing
glial cells were found in BD cases. This is in agreement with
earlier ﬁndings by Toro et al. (2006), but in contrast to reduced
GS expression in prefrontal area of BD subjects as reported by
Choudary et al. (2005). Two possible conclusions may be drawn
from our data: either (1) glia associated-GS is normal, because
GS does not play a prominent role in the pathophysiology of
BD, and/or (2) GS expression was “normalized” (most probably
up-regulated) by long-term treatment of the disease. Given the
latter possibility, two putative factors might have increased GS
expression in brains of BD subjects: administration of lithium
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(Kalkman, 2011) and treatment with antidepressants (Hashioka
et al., 2013; Liu et al., 2015). Our calculations, however, did
not reveal signiﬁcant positive correlations of numerical densities
of GS expressing glial cells and either of the aforementioned
two factors. Hence we tend to believe that GS is not a
major contributing factor to BD neuropathology. It should be
stated, however, that disease-related alterations in the cerebral
expression of GS do not always exert a direct inﬂuence
on the glutamate–glutamine–GABA ratio. So, for example,
a strong upregulation of GS protein was reported for the
anterior cingulate cortex of female but not male individuals
with schizophrenia (Martins-de-Souza et al., 2010), whereas
no such gender-speciﬁc change in the Glx ratio was found in
schizophrenia patients by MRS (Rowland et al., 2013). Thus,
further studies are clearly needed to learn more about the impact
of GS on glutamate metabolites in the brain.
Limitations of the Study
Since a major limitation of post-mortem studies is underpowered
sample size, we have tried to increase the three cohorts (controls,
N = 16; BD, N = 15, MDD, N = 14). A consequence from
doing so is to accept the lack of data on the cumulative
antidepressant exposure of some patients with MDD and
BD. A further limitation of the this study is that, as in all
immunocytochemistry-based morphometric studies, it cannot be
said with ultimate certainty, whether the observed disease-related
changes are due to glial cell loss, or to reduced intracellular
expression of the protein (below the detection threshold of
the method) in still existing cells, or both. Lastly, a limitation
may arise from the fact that the decreased expression of GS
protein does not necessarily mean reduced activity of the enzyme.
Unfortunately, it is impossible to reveal the catalytic activity
of the AC-located GS enzyme because of the lack of a speciﬁc
enzyme histochemical method for GS.
Conclusion
In MDD but not in BD there is a glia cell-type speciﬁc
(astroglial) reduction of cortical GS protein expression, which
might constitute a cellular correlate of lower cortical Glx levels
reported for subjects with MDD in MSR studies.
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